FIELD: pharmaceuticals.
SUBSTANCE: invention relates to crystalline (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazin-1(6H)-carboxamide, which is characterized by diffraction peaks at diffraction angle (2θ±0.2°) 5.8°, 6.4°, 8.0°, 10.1°, 12.8°, 14.2°, 16.0°, 18.9°, 19.7°and 23.1° according to measurement by means of powder X-ray diffraction. Invention also relates to said compound having different characteristics, and to a pharmaceutical composition.
EFFECT: obtaining a novel crystalline form (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazin-1(6H)-carboxamide, having activity with respect to Wnt path modulation.
5 cl, 1 tbl, 21 ex, 6 dwg
